Leonard Braden Michael
CIK 0001373603 Name as filed on the most recent filing
Filed as Leonard Braden Michael (108)
224 transaction lines · from 108 filings · filed 2009-11-25 to 2026-04-27 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Aclaris Therapeutics, Inc. 8 filings
- ISSUER Adverum Biotechnologies, Inc. 11 filings
- ISSUER Astrotech Corp 8 filings
- ISSUER An2 Therapeutics, Inc. 3 filings
- ISSUER Reneo Pharmaceuticals, Inc. 5 filings
- ISSUER Talis Biomedical Corp 4 filings
- ISSUER Avrobio, Inc. 1 filings
- ISSUER Cyteir Therapeutics, Inc. 2 filings
- ISSUER Imara Inc. 9 filings
- ISSUER Retractable Technologies Inc 7 filings
- ISSUER Metacrine, Inc. 4 filings
- ISSUER Satsuma Pharmaceuticals, Inc. 2 filings
- ISSUER Gemini Therapeutics, Inc. /DE 2 filings
- ISSUER ProPhase Labs, Inc. 7 filings
- ISSUER Build A Bear Workshop Inc 35 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
217 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-04-23 |
Aclaris Therapeutics, Inc. ACRS |
S, Open-market sale | 300,000 disposed | 4.53 | 1,359,000.00 | Form 4, filing 0001373604-26-000034 | |
| 2025-12-04 |
Adverum Biotechnologies, Inc. ADVM |
S, Open-market sale | 524,560 disposed | 4.19 | 2,200,371.83 | Form 4, filing 0001373604-25-000122 | |
| 2025-12-03 |
Adverum Biotechnologies, Inc. ADVM |
S, Open-market sale | 222,925 disposed | 4.17 | 929,597.25 | Form 4, filing 0001373604-25-000118 | |
| 2025-12-02 |
Adverum Biotechnologies, Inc. ADVM |
S, Open-market sale | 51,961 disposed | 4.20 | 218,236.20 | Form 4, filing 0001373604-25-000118 | |
| 2025-12-01 |
Adverum Biotechnologies, Inc. ADVM |
S, Open-market sale | 300,000 disposed | 4.20 | 1,260,000.00 | Form 4, filing 0001373604-25-000118 | |
| 2025-10-03 |
Astrotech Corp ASTC |
S, Open-market sale | 220,410 disposed | 7.13 | 1,571,633.50 | Form 4, filing 0001373604-25-000106 | |
| 2025-10-03 |
Astrotech Corp ASTC |
S, Open-market sale | 9,166 disposed | 5.83 | 53,437.78 | Form 4, filing 0001373604-25-000106 | |
| 2025-05-30 |
An2 Therapeutics, Inc. ANTX |
S, Open-market sale | 425,000 disposed | 1.01 | 429,250.00 | Form 4, filing 0001373604-25-000084 | |
| 2025-05-30 |
An2 Therapeutics, Inc. ANTX |
S, Open-market sale | 7,000 disposed | 1.03 | 7,226.80 | Form 4, filing 0001373604-25-000084 | |
| 2025-05-28 |
An2 Therapeutics, Inc. ANTX |
S, Open-market sale | 2,000,000 disposed | 1.16 | 2,320,000.00 | Form 4, filing 0001373604-25-000084 | |
| 2025-05-28 |
An2 Therapeutics, Inc. ANTX |
S, Open-market sale | 100,000 disposed | 1.16 | 116,000.00 | Form 4, filing 0001373604-25-000084 | |
| 2025-05-28 |
An2 Therapeutics, Inc. ANTX |
S, Open-market sale | 200,000 disposed | 1.09 | 218,000.00 | Form 4, filing 0001373604-25-000090 | |
| 2025-04-23 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 50,000 acquired | 2.98 | 148,950.00 | Form 4, filing 0001373604-25-000065 | |
| 2025-04-22 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 300,000 acquired | 3.00 | 900,000.00 | Form 4, filing 0001373604-25-000065 | |
| 2025-04-02 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 15,209 acquired | 4.04 | 61,407.86 | Form 4, filing 0001373604-25-000058 | |
| 2025-03-31 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 19,566 acquired | 4.38 | 85,667.77 | Form 4, filing 0001373604-25-000058 | |
| 2025-03-27 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 16,593 acquired | 5.19 | 86,089.46 | Form 4, filing 0001373604-25-000069 | |
| 2025-03-27 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 16,593 disposed | 5.19 | 86,089.46 | Form 4, filing 0001373604-25-000056 | |
| 2025-03-27 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 16,593 acquired | 5.19 | 86,089.46 | Form 4, filing 0001373604-25-000067 | |
| 2025-03-26 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 20,407 acquired | 5.04 | 102,841.08 | Form 4, filing 0001373604-25-000069 | |
| 2025-03-26 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 20,407 acquired | 5.04 | 102,841.08 | Form 4, filing 0001373604-25-000056 | |
| 2025-03-26 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 20,407 acquired | 5.04 | 102,841.08 | Form 4, filing 0001373604-25-000067 | |
| 2025-03-20 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 30,600 acquired | 5.61 | 171,766.98 | Form 4, filing 0001373604-25-000051 | |
| 2025-03-19 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 25,000 acquired | 4.94 | 123,390.00 | Form 4, filing 0001373604-25-000051 | |
| 2025-03-18 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 44,341 acquired | 4.73 | 209,617.64 | Form 4, filing 0001373604-25-000051 | |
| 2025-03-18 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 18,000 acquired | 4.60 | 82,800.00 | Form 4, filing 0001373604-25-000051 | |
| 2025-02-28 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 85,068 acquired | 4.60 | 391,015.06 | Form 4, filing 0001373604-25-000041 | |
| 2025-02-27 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 86,802 acquired | 4.46 | 387,093.52 | Form 4, filing 0001373604-25-000041 | |
| 2025-02-26 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 164,886 acquired | 4.01 | 660,978.51 | Form 4, filing 0001373604-25-000041 | |
| 2024-09-25 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 68,746 acquired | 1.50 | 102,871.51 | Form 4, filing 0001373604-24-000098 | |
| 2024-09-24 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 29,600 acquired | 1.41 | 41,866.24 | Form 4, filing 0001373604-24-000098 | |
| 2024-09-18 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 806 acquired | 1.40 | 1,128.40 | Form 4, filing 0001373604-24-000094 | |
| 2024-09-17 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 55,300 acquired | 1.36 | 75,108.46 | Form 4, filing 0001373604-24-000094 | |
| 2024-09-16 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 172,747 acquired | 1.37 | 236,870.69 | Form 4, filing 0001373604-24-000090 | |
| 2024-09-13 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 150,000 acquired | 1.31 | 196,950.00 | Form 4, filing 0001373604-24-000090 | |
| 2024-09-12 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 36,176 acquired | 1.40 | 50,523.40 | Form 4, filing 0001373604-24-000090 | |
| 2024-09-06 |
Talis Biomedical Corp TLIS |
P, Open-market purchase | 25,000 acquired | 1.48 | 37,100.00 | Form 4, filing 0001373604-24-000088 | |
| 2024-09-05 |
Talis Biomedical Corp TLIS |
P, Open-market purchase | 5,100 acquired | 1.40 | 7,140.00 | Form 4, filing 0001373604-24-000088 | |
| 2024-09-03 |
Talis Biomedical Corp TLIS |
P, Open-market purchase | 500 acquired | 4.00 | 2,000.00 | Form 4, filing 0001373604-24-000086 | |
| 2024-08-30 |
Talis Biomedical Corp TLIS |
P, Open-market purchase | 151 acquired | 4.25 | 641.75 | Form 4, filing 0001373604-24-000084 | |
| 2024-08-28 |
Talis Biomedical Corp TLIS |
P, Open-market purchase | 1,215 acquired | 3.96 | 4,814.68 | Form 4, filing 0001373604-24-000081 | |
| 2024-08-26 |
Talis Biomedical Corp TLIS |
P, Open-market purchase | 13,167 acquired | 3.90 | 51,322.33 | Form 4, filing 0001373604-24-000081 | |
| 2024-08-14 |
An2 Therapeutics, Inc. ANTX |
P, Open-market purchase | 1,500,000 acquired | 1.04 | 1,560,000.00 | Form 4, filing 0001373604-24-000066 | |
| 2024-08-14 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 100,487 acquired | 1.41 | 142,008.23 | Form 4, filing 0001373604-24-000071 | |
| 2024-08-13 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 171,339 acquired | 1.39 | 238,589.56 | Form 4, filing 0001373604-24-000071 | |
| 2024-08-05 |
Aclaris Therapeutics, Inc. ACRS |
P, Open-market purchase | 206,025 acquired | 1.24 | 256,356.91 | Form 4, filing 0001373604-24-000060 | |
| 2024-08-02 |
Aclaris Therapeutics, Inc. ACRS |
P, Open-market purchase | 167,544 acquired | 1.29 | 216,399.83 | Form 4, filing 0001373604-24-000060 | |
| 2024-07-31 |
Aclaris Therapeutics, Inc. ACRS |
P, Open-market purchase | 100,000 acquired | 1.33 | 132,640.00 | Form 4, filing 0001373604-24-000056 | |
| 2024-07-30 |
Aclaris Therapeutics, Inc. ACRS |
P, Open-market purchase | 173,730 acquired | 1.30 | 226,370.19 | Form 4, filing 0001373604-24-000056 | |
| 2024-07-30 |
Adverum Biotechnologies, Inc. ADVM |
P, Open-market purchase | 85,800 acquired | 7.15 | 613,470.00 | Form 4, filing 0001373604-24-000058 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 144
- Open-market sale 73
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Leonard Braden Michael, insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001373603
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6